Glycadia, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the prevention and treatment of vascular complications of diabetes.
WHAT WE DO
Glycadia’s science is based on recent discoveries concerning the causal role of circulating glycated proteins in the development of complications of diabetes involving the kidney, eye, and other organs. The process of nonenzymatic glycation is accelerated in diabetes, giving rise to elevated amounts of glucose-modified proteins that trigger untoward cellular events and promote organ damage. The company’s drug development programs are focused on inhibiting the excess nonenzymatic glycation of key proteins to reduce the burden of these blood-borne factors that trigger abnormalities in cell signaling pathways and molecular mediators that underlie diabetic nephropathy, retinopathy, and cardiovascular disease, which continue to occur and progress despite the availability of newer glucose-lowering agents.